Research Progress on Ferroptosis Associated Mechanisms in Amyotrophic Lateral Sclerosis

doi:10.3870/j.issn.1672-8009.2025.06.014

Abstract

Abstract: Amyotrophic lateral sclerosis(ALS)is a fatal neurodegenerative disease,and the selective death of motor neurons is its prominent pathological feature.The mechanisms triggering the death of ALS neurons are intricate.Currently,there is no effective treatment plan.It is urgent to deeply explore the potential disease mechanisms and search for neuroprotective agents that may delay disease progression,extend survival,and ultimately reduce the disease burden.Ferroptosis is a programmed cell death mode mediated by iron ions,which causes neuronal damage through lipid peroxidation and oxidative stress.Recent studies have revealed that ferroptosis is closely related to the pathological mechanism of ALS and may become a potential therapeutic target.This article reviews the molecular mechanisms of ferroptosis,pathological characteristics of ALS,and potential connections between the two.It also explores the latest advances in clinical trials targeting ferroptosis for the treatment of ALS,with the aim of opening up new avenues for ALS treatment.

Key words: amyotrophic lateral sclerosis, ferroptosis, lipid peroxidation

CLC Number:

R743.35

LI Shujie, QI Yan, SUN Zhitang. Research Progress on Ferroptosis Associated Mechanisms in Amyotrophic Lateral Sclerosis[J]. Journal of Medical Molecular Biology, 2025, 22(6): 623-629.

References

[1] VIDOVIC M,MÜSCHEN L H,BRAKEMEIER S,et al.current state and future directions in the diagnosis of amyotrophic lateral sclerosis[J].Cells,2023,12(5):736.
[2] MEAD R J,SHAN N,REISER H J,et al.Amyotrophic lateral sclerosis:a neurodegenerative disorder poised for successful therapeutic translation[J].Nat Rev Drug Discov,2023,22(3):185-212.
[3] NGUYEN L.Updates on disease mechanisms and therapeutics for amyotrophic lateral sclerosis[J].Cells,2024,13(11):888.
[4] PICCOLO M,FERRARO M G,IAZZETTI F,et al.Insight into iron,oxidative stress and ferroptosis:Therapy targets for approaching anticancer strategies[J].Cancers(Basel),2024,16(6):1220.
[5] WU L,XIAN X,TAN Z,et al.The role of iron metabolism,lipid metabolism,and redox homeostasis in Alzheimer’s disease:from the perspective of ferroptosis[J].Mol Neurobiol,2023,60(5):2832-2850.
[6] ZHANG L,BAI X Y,SUN K Y,et al.A new perspective in the treatment of ischemic stroke:ferroptosis[J].Neurochem Res,2024,49(4):815-833.
[7] LEI G,ZHUANG L,GAN B.Targeting ferroptosis as a vulnerability in cancer[J].Nat Rev Cancer,2022,22(7):381-396.
[8] STOCKWELL B R.Ferroptosis turns 10:Emerging mechanisms,physiological functions,and therapeutic applications[J].Cell,2022,185(14):2401-2421.
[9] LI Z,ZHANG Y,JI M,et al.Targeting ferroptosis in neuroimmune and neurodegenerative disorders for the development of novel therapeutics[J].Biomed Pharmacother,2024,176:116777.
[10] LIU M R,ZHU W T,PEI D S.System Xc^-:a key regulatory target of ferroptosis in cancer[J].Invest New Drugs,2021,39(4):1123-1131.
[11] XIE Y,KANG R,KLIONSKY D J,et al.GPX4 in cell death,autophagy,and disease[J].Autophagy,2023,19(10):2621-2638.
[12] LIU Y,WAN Y,JIANG Y,et al.GPX4:The hub of lipid oxidation,ferroptosis,disease and treatment[J].Biochim Biophys Acta Rev Cancer,2023,1878(3):188890.
[13] DROBNIC F,LIZARRAGA M A,CABALLERO-GARCĬA A,et al.Coenzyme Q10 supplementation and its impact on exercise and sport performance in humans:A recovery or a performance-enhancing molecule?[J].Nutrients,2022,14(9):1811.
[14] BERSUKER K,HENDRICKS J M,LI Z,et al.The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis[J].Nature,2019,575(7784):688-692.
[15] KRAFT VA N,BEZJIAN C T,PFEIFFER S,et al.GTP cyclohydrolase1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling[J].ACS Cent Sci,2020,6(1):41-53.
[16] QIU S,ZHONG X,MENG X,et al.Mitochondria-localized cGAS suppresses ferroptosis topromote cancer progression[J].Cell Res,2023,33(4):299-311.
[17] YAN R,LIN B,JIN W,et al.NRF2,A superstar of ferroptosis[J].Antioxidants(Basel),2023,12(9):1739.
[18] MITSUMOTO H,KASARSKIS E J,SIMMONS Z.Hastening the diagnosis of amyotrophic lateral sclerosis[J].Neurology,2022,99(2):60-68.
[19] KHOSHDOOZ S,ABBASI H,ABBASI M M.Iron-status indicators and HFE gene polymorphisms in individuals with amyotrophic lateral sclerosis:An umbrella review of meta-analyses and systematic reviews[J].Biol TraceElem Res,2025,203(6):2974-2985.
[20] GHADERI S,FATEHI F,KALRA S,et al.Quantitative susceptibility mapping in amyotrophic lateral sclerosis:automatic quantification of the magnetic susceptibility in the subcortical nuclei[J].Amyotroph Lateral Scler Frontotemporal Degener,2025,26(1-2):73-84.
[21] LIDDELL J R,HILTON J B W,KYSENIUS K,et al.Microglial ferroptotic stress causes non-cell autonomous neuronal death[J].Mol Neurodegener,2024,19(1):14.
[22] WANG D,LIANG W,HUO D,et al.SPY1 inhibits neuronal ferroptosis in amyotrophic lateral sclerosis by reducing lipid peroxidation through regulation of GCH1 and TFR1[J].Cell Death Differ,2023,30(2):369-382.
[23] MOREAU C,DANEL V,DEVEDJIAN J C,et al.Could conservative iron chelation lead to neuroprotectionin amyotrophic lateral sclerosis?[J].Antioxid Redox Signal,2018,29(8):742-748.
[24] KUPERSHMIDT L,YOUDIM M B H.The Neuroprotective activities of the novel multi-target iron-chelators in models of Alzheimer’s disease,amyotrophic lateral sclerosis and aging[J].Cells,2023,12(5):763.
[25] YOON J H,SEO Y,JO Y S,et al.Brain lipidomics:From functional landscape to clinical significance[J].Sci Adv,2022,8(37):eadc9317.
[26] PETROVIC S,ARSIC A,RISTIC-MEDIC D,et al.Lipid peroxidation and antioxidant supplementation in neurodegenerative diseases:A review of human studies[J].Antioxidants(Basel),2020,9(11):1128.
[27] HEMERKOVÁ P,VALIŠ M.Role of oxidative stress in the pathogenesis of amyotrophic lateral sclerosis:Antioxidant metalloenzymes and therapeutic strategies[J].Biomolecules,2021,11(3):437.
[28] WANG L,FANG X,LING B,et al.Research progress on ferroptosis in the pathogenesis and treatment of neurodegenerative diseases[J].Front Cell Neurosci,2024,18:1359453.
[29] WANG T,TOMAS D,PERERA N D,et al.Ferroptosis mediates selective motor neuron death in amyotrophic lateral sclerosis[J].Cell Death Differ,2022,29(6):1187-1198.
[30] CHEN L,NA R,DANAE MCLANE K,et al.Overexpression of ferroptosis defense enzyme Gpx4 retards motor neuron disease of SOD1 G93A mice[J].Sci Rep,2021,11(1):12890.
[31] TU L F,ZHANG T Z,ZHOU Y F,et al.GPX4 deficiency-dependent phospholipid peroxidation drives motor deficits of ALS[J].J Adv Res,2023,43:205-218.
[32] WANG Y,LV M N,ZHAO W J.Research on ferroptosis as a therapeutic target for the treatment of neurodegenerative diseases[J].Ageing Res Rev,2023,91:102035.
[33] XIANG Y,SONG X,LONG D.Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseases[J].Arch Toxicol,2024,98(3):579-615.
[34] PROVENZANO F,TORAZZA C,BONIFACINO T,et al.The key role of astrocytes in amyotrophic lateral sclerosis and their commitment to glutamate excitotoxicity[J].Int J Mol Sci,2023,24(20):15430.
[35] AL-NASSER M N,MELLOR I R,CARTER W G.Is L-glutamate toxicto neurons and thereby contributes to neuronal loss and neurodegeneration? A systematic review[J].Brain Sci,2022,12(5):577.
[36] VUKOLOVA M N,YEN L Y,KHMYZ M I,et al.Parkinson’s disease,epilepsy,and amyotrophic lateral sclerosis—emerging role of AMPA and kainate subtypes of ionotropic glutamate receptors[J].Front Cell Dev Biol,2023,11:1252953.
[37] CALAFATTI M,COCOZZA G,LIMATOLA C,et al.Microglial crosstalk with astrocytes and immune cells in amyotrophic lateral sclerosis[J].Front Immunol,2023,14:1223096.
[38] DENG L,HE S,GUO N,et al.Molecular mechanisms of ferroptosis and relevance to inflammation[J].Inflamm Res,2023,72(2):281-299.
[39] XU Y,JIA B,LI J,et al.The interplay between ferroptosis and neuroinflammation in central neurological disorders[J].Antioxidants(Basel),2024,13(4):395.
[40] LIDDELL J R,HILTON J B W,KYSENIUS K,et al.Microglial ferroptotic stress causes non-cell autonomous neuronal death[J].Mol Neurodegener,2024,19(1):14.
[41] LI J,JIA Y C,DING Y X,et al.The crosstalk between ferroptosis and mitochondrial dynamic regulatory networks[J].Int J Biol Sci,2023,19(9):2756-2771.
[42] ZHAO J,WANG X,HUO Z,et al.The impact of mitochondrial dysfunction in amyotrophic lateral sclerosis[J].Cells,2022,11(13):2049.
[43] DEVOS D,CABANTCHIK Z I,MOREAU C,et al.Conservative iron chelation for neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis[J].J Neural Transm(Vienna),2020,127(2):189-203.
[44] SOUTHON A,SZOSTAK K,ACEVEDO K M,et al.CuII(atsm)inhibits ferroptosis:Implications for treatment of neurodegenerative disease[J].Br J Pharmacol,2020,177(3):656-667.
[45] LUM J S,BROWN M L,FARRAWELL N E,et al.CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1G93A mice with a C57BL/6 background[J].Sci Rep,2021,11(1):19392.
[46] DENNYS C N,ROUSSEL F,RODRIGO R,et al.CuATSM effectively ameliorates ALS patient astrocyte-mediated motor neuron toxicity in human in vitro models of amyotrophic lateral sclerosis[J].Glia,2023,71(2):350-365.
[47] GAO L,GIANNOUSIS P,THOOLEN M,et al.First-in-human studies of pharmacokinetics and safety of utreloxastat(PTC857),a novel 15-lipooxygenase inhibitor for the treatment of amyotrophic lateral sclerosis[J].Clin Pharmacol Drug Dev,2023,12(2):141-151.